D. Skarlos
- Co-authors
- G. KlouvasGeorge FountzilasP. KosmidisN. MylonakisD. TheocharisE. PapadakisNicholas PavlidisPh. Palamidas
- Topics
- Cancer Treatment and Pharmacology (6 papers)Lung Cancer Treatments and Mutations (4 papers)Lung Cancer Research Studies (3 papers)
- Partner nations
- Greece
In The Last Decade
D. Skarlos
16 papers receiving 352 citations
Peers
Comparison fields: 5 of 48
- Oncology 282
- Epidemiology 181
- Molecular Biology 131
- Pulmonary and Respiratory Medicine 100
- Surgery 31
Countries citing papers authored by D. Skarlos
This map shows the geographic impact of D. Skarlos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Skarlos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Skarlos more than expected).
Fields of papers citing papers by D. Skarlos
This network shows the impact of papers produced by D. Skarlos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Skarlos. The network helps show where D. Skarlos may publish in the future.
Co-authorship network of co-authors of D. Skarlos
This figure shows the co-authorship network connecting the top 25 collaborators of D. Skarlos. A scholar is included among the top collaborators of D. Skarlos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Skarlos. D. Skarlos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. | 5 |
| 2 | Performance status (PS): a simple predictor of short-term outcome of cancer patients with solid tumors admitted to the intensive care unit (ICU). | 30 |
| 3 | 2 | |
| 4 | 27 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 7 | |
| 8 | Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer. | 18 |
| 9 | Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study. | 17 |
| 10 | 2 | |
| 11 | Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. | 12 |
| 12 | 3 | |
| 13 | Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. | 9 |
| 14 | 9 | |
| 15 | 195 | |
| 16 | 25 |
About D. Skarlos
D. Skarlos is a scholar working on Oncology, Reproductive Medicine and Otorhinolaryngology, having authored 16 papers that have together received 363 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Research Studies (3 papers). The work is most often cited by research in Oncology (282 citations), Epidemiology (181 citations) and Otorhinolaryngology (14 citations). D. Skarlos has collaborated with scholars based in Greece. Frequent co-authors include G. Klouvas, George Fountzilas, P. Kosmidis, N. Mylonakis, D. Theocharis, E. Papadakis, Nicholas Pavlidis, Ph. Palamidas, Ekaterini Boleti and E. Samantas. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.